Published in Pharm Res on February 25, 2010
Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research. Carcinogenesis (2012) 1.27
Molecular targets of isothiocyanates in cancer: recent advances. Mol Nutr Food Res (2014) 1.08
Notch activation by phenethyl isothiocyanate attenuates its inhibitory effect on prostate cancer cell migration. PLoS One (2011) 0.90
Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin. Mol Nutr Food Res (2011) 0.88
Phenethyl isothiocyanate: a comprehensive review of anti-cancer mechanisms. Biochim Biophys Acta (2014) 0.88
Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells. Exp Hematol Oncol (2014) 0.83
Phenethyl isothiocyanate suppresses inhibitor of apoptosis family protein expression in prostate cancer cells in culture and in vivo. Prostate (2011) 0.81
In vitro and in vivo effects of phenethyl isothiocyanate treatment on vimentin protein expression in cancer cells. Nutr Cancer (2013) 0.80
The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC. J Cell Mol Med (2014) 0.80
CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cells. Cancer Prev Res (Phila) (2015) 0.78
Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway. Cancer Biol Ther (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Natural products as sources of new drugs over the period 1981-2002. J Nat Prod (2003) 8.03
The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry (2001) 6.35
Prostate cancer. N Engl J Med (2003) 5.91
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep (2006) 4.15
Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst (1995) 3.67
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med (1998) 2.78
Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev (1996) 2.58
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate (1983) 2.29
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res (2005) 2.21
Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis (2003) 2.20
Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene (2004) 2.02
Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene (2005) 1.96
Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev (2000) 1.96
Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res (2003) 1.83
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res (2008) 1.76
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res (2006) 1.61
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res (2007) 1.61
Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J Biol Chem (2008) 1.47
Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J Natl Cancer Inst (1977) 1.46
The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem (2008) 1.46
Selected isothiocyanates rapidly induce growth inhibition of cancer cells. Mol Cancer Ther (2003) 1.43
Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res (2007) 1.42
Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene (2006) 1.40
STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells . Prostate (2000) 1.40
Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res (2009) 1.39
Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction. Clin Cancer Res (2006) 1.38
Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylmethylamine carcinogenesis in the rat esophagus. Cancer Res (1991) 1.38
X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther (2004) 1.36
Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. Cancer Res (2008) 1.35
Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res (2002) 1.34
Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis (2006) 1.33
Caspase-dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous vegetable-derived cancer chemopreventive agent, is mediated by Bak and Bax. Clin Cancer Res (2005) 1.33
Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther (2004) 1.29
Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase. J Biol Chem (2002) 1.24
High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. Anal Biochem (2001) 1.20
Pharmacokinetics of dietary phenethyl isothiocyanate in rats. Pharm Res (2005) 1.15
Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev (2006) 1.14
Determination of phenethyl isothiocyanate in human plasma and urine by ammonia derivatization and liquid chromatography-tandem mass spectrometry. Anal Biochem (2003) 1.13
New paradigms for advanced prostate cancer. Rev Urol (2007) 1.09
Effects of aromatic isothiocyanates on tumorigenicity, O6-methylguanine formation, and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Cancer Res (1989) 1.08
Complete androgen blockade for prostate cancer: what went wrong? J Urol (2000) 1.06
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res (2005) 1.05
X-linked inhibitor of apoptosis protein as a therapeutic target. Expert Opin Ther Targets (2007) 1.02
PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells. Prostate (2006) 1.00
Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J Natl Cancer Inst (1994) 0.99
Role of mitogen-activated protein kinases in phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells. Mol Carcinog (2005) 0.98
Effects of phenethyl isothiocyanate and benzyl isothiocyanate, individually and in combination, on lung tumorigenesis induced in A/J mice by benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Lett (2000) 0.96
Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-RAS oncogene transformed tumor growth in vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Biochem Biophys Res Commun (1996) 0.92
Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer. Int J Cancer (2008) 0.85
Recent progress in management of advanced prostate cancer. Oncology (Williston Park) (2005) 0.84
Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with and without neo-adjuvant hormonal therapy. J Cancer Res Clin Oncol (2009) 0.82
Diallyl trisulfide-induced apoptosis in human cancer cells is linked to checkpoint kinase 1-mediated mitotic arrest. Mol Carcinog (2009) 0.91
Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS One (2013) 0.88
Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma. Mol Cancer (2014) 0.87